Plasma HIV Viral Rebound following Protocol-Indicated Cessation of ART Commenced in Primary and Chronic HIV Infection

• Elizabeth Hamlyn ,

  * E-mail: e.hamlyn@nhs.net

  Affiliations Kings College Hospital National Health Service Foundation Trust, London, United Kingdom, Imperial College, London, United Kingdom

  ⨯
• Fiona M. Ewings,

  Affiliation Medical Research Council Clinical Trials Unit, London, United Kingdom

  ⨯
• Kholoud Porter,

  Affiliation Medical Research Council Clinical Trials Unit, London, United Kingdom

  ⨯
• David A. Cooper,

  Affiliation The National Centre in HIV Epidemiology & Clinical Research and the University of New South Wales, Sydney, Australia

  ⨯
• Giuseppe Tambussi,

  Affiliation Vaccine and Immunotherapy Research Centre, San Raffaele Scientific Institute, Milan, Italy

  ⨯
• Mauro Schechter,

  Affiliation Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

  ⨯
• Court Pedersen,

  Affiliation Odense University Hospital, Odense, Denmark

  ⨯
• Jason F. Okulicz,

  Affiliations Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America, San Antonio Military Medical Center, Fort Sam Houston, Texas, United States of America

  ⨯
• Myra McClure,

  Affiliation Imperial College, London, United Kingdom

  ⨯
• Abdel Babiker,

  Affiliation Medical Research Council Clinical Trials Unit, London, United Kingdom

  ⨯
• Jonathan Weber,

  Affiliation Imperial College, London, United Kingdom

  ⨯
• Sarah Fidler,

  Affiliation Imperial College, London, United Kingdom

  ⨯
• on behalf of the INSIGHT SMART and SPARTAC Investigators